Aileron Therapeutics Short Long Term Debt Total Over Time
| ALRN Stock | USD 2.86 0.12 4.38% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Aileron Therapeutics Performance and Aileron Therapeutics Correlation. Aileron |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Return On Assets (0.26) | Return On Equity (0.44) |
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Short Long Term Debt Total Analysis
Compare Aileron Therapeutics and related stocks such as Applied Molecular, Catalyst Biosciences, and Bio Path Holdings Short Long Term Debt Total Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPTH | 196.4 K | 415 K | 415 K | 415 K | 415 K | 415 K | 415 K | 415 K | 415 K | 415 K | 330 K | 235 K | 221 K | 113 K | 175.6 K |
| BNTC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 405 K | 213 K | 811 K | 559 K | 284 K | 277.7 K |
| ARTL | 95 K | 95 K | 95 K | 95 K | 95 K | 95 K | 95 K | 95 K | 95 K | 95 K | 95 K | 95 K | 63 K | 56.7 K | 63.2 K |
| HSTO | 1000 K | 1000 K | 1000 K | 1000 K | 1000 K | 1000 K | 1000 K | 13.2 M | 145 K | 145 K | 5.3 M | 4.7 M | 4.6 M | 5.3 M | 3.9 M |
| ABVC | 30 K | 1.2 M | 1.1 M | 1.1 M | 1.1 M | 7 K | 1.2 M | 1.2 M | 800 K | 4.6 M | 6.5 M | 3.1 M | 3.1 M | 2.3 M | 1.9 M |
| CTMX | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 3 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 18.1 M | 18.1 M | 14 M | 16.8 M |
| ASMB | 5.8 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 10.1 M | 6.5 M | 3.5 M | 2.3 M | 2.2 M |
| TIL | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 86.1 M | 91.3 M |
| NUVB | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 4.3 M | 4 M | 4.2 M |
| SLRX | 502.3 K | 502.3 K | 502.3 K | 502.3 K | 502.3 K | 502.3 K | 502.3 K | 502.3 K | 502.3 K | 502.3 K | 477 K | 289.6 K | 289.6 K | 260.7 K | 338.4 K |
| SABS | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 8.1 M | 6.7 M | 5.9 M | 5.9 M | 5.5 M |
| VCNX | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 2.8 M | 9.2 M | 9.2 M | 9.2 M | 390 K | 485 K | 247 K | 234.7 K |
| GOVX | 43.2 K | 677.3 K | 129.4 K | 60 K | 78.9 K | 300 K | 300 K | 300 K | 300 K | 39.7 K | 198.1 K | 198.1 K | 198.1 K | 178.3 K | 169.3 K |
Aileron Therapeutics and related stocks such as Applied Molecular, Catalyst Biosciences, and Bio Path Holdings Short Long Term Debt Total description
My Equities
My Current Equities and Potential Positions
| Aileron Therapeutics | ALRN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.86
Check out Aileron Therapeutics Performance and Aileron Therapeutics Correlation. To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Aileron Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.